Iambic Therapeutics Prices $150 Million Initial Public Offering
MT Newswires Live
Oct 15
Iambic Therapeutics (IAM) priced its initial public offering of about 9.38 million shares at $16.00 each, it said late Wednesday, targeting about $150 million in gross proceeds.
The company, which is offering all the shares in the sale, said it has granted underwriters a 30-day option to purchase up to about 1.41 million additional shares.
Shares are expected to begin trading on the Nasdaq Global Select Market on Thursday, under the ticker symbol "IAM," Iambic said.
The offering is expected to close Friday, subject to customary closing conditions, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.